Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Bristol-Myers Squibb Company stock (US0897961004): Is its oncology dominance strong enough to unlock
This article analyzes Bristol-Myers Squibb’s (BMS) market position, focusing on its dominance in oncology and immunology with blockbuster drugs like Opdivo and Eliquis. It discusses the company’s core business model, product portfolio, competitive landscape, and its appeal to U.S. and English-speaking market investors, despite looming patent cliffs and pipeline uncertainties. Analysts express cautious optimism, highlighting the need for pipeline success to offset future revenue losses.